The report "Drug Screening Market by Product (Consumables, Urine Testing Devices, Analytical, Breathalyzer, Chromatography, Immunoassay) & Services, Sample Type (Urine, Breath), End User (Workplace, Laboratories, Criminal Justice, Hospitals) - Global Forecast to 2026" The global drug screening market is projected to reach USD 11.6 billion by 2026, from USD 5.3 billion in 2021, at a CAGR of 16.8% during the forecast period. The rising drug & alcohol consumption, the enforcement of stringent laws mandating drug and alcohol testing, government funding in major markets, and regulatory approvals and product and service launches are the major factors driving the growth of this market.

Request Sample Copy of this Report @

Drug screening is an important part of many industries and institutions. It is used to assess whether or not an individual has been using drugs, and depending on the industry, it can be used to determine if an individual is suitable for a particular role.

Drug screening is often used in the workplace to determine if an employee is abusing drugs or alcohol. It can help employers ensure that their employees are sober and not under the influence of drugs or alcohol while at work. Drug screening can also help to protect employers from liability if an employee is injured on the job due to drug or alcohol use.Drug screening is also used in healthcare settings to determine if a patient is taking any medications that could interact negatively with other drugs. This helps healthcare providers provide the best possible care for their patients.

Drug screening can also be used in the legal system. Police officers may use drug testing to determine if an individual has been using drugs. It can also be used in court to determine if an individual is guilty of a crime involving drugs or alcohol. No matter what the purpose of drug screening is, it is important to make sure that it is done properly and in accordance with laws and regulations. Drug screening should always be done in a safe, secure, and private setting. It is also important to make sure that the results of the drug screening are kept confidential.

Customize the Full Report Based on Your Requirements @

Key Market Players

The drug screening market is highly competitive and populated by several big and small players. Prominent players offering drug screening products and services include LabCorp (US), Quest Diagnostics (US), Abbott Laboratories (US), Thermo Fisher Scientific, Inc. (US), Alfa Scientific Designs, Inc. (US),  OraSure Technologies, Inc. (US), Siemens Healthineers (Germany), Roche (Switzerland), MPD Inc. (US), Shimadzu (Japan), LifeLoc Technologies (US), Drägerwerk (Germany), Premier Biotech, Inc. (US), Omega Laboratories, Inc. (US), Psychemedics (US), Clinical Reference Laboratory (US), American Bio Medica Corporation (US), ACM Global Laboratories (US), CareHealth America Corp (US), Sciteck, Inc. (US), Synens (France), Intoximeters (US), AccuSource (US), Cordant Health Solutions (US), Millennium Health (US).

LabCorp (US): LabCorp is a leading player in the US drug screening services market. The company’s leading position is attributed to its wide drug testing portfolio, including over 4,800 tests. The company has a strong brand name and robust service portfolio, which provides drug screening services to managed care organizations, governmental agencies, healthcare providers, hospitals and health systems, employers, patients, consumers, contract research organizations, food and nutritional companies, and independent clinical laboratories.

Abbott Laboratories (US): Abbott Laboratories has a strong product portfolio, and its FDA and CE Mark-approved products have helped the company enhance its presence in the drug screening market. Abbott provides abuse testing products and services for many settings such as hospitals, physician offices, criminal justice agencies, workplaces, rehabilitation centers, occupational health clinics, and homes. The company has a strong presence in the US and seeks to enhance its geographical presence by strengthening its business operations in emerging markets such as India and China.

North America to dominate the drug screening market

North America is expected to dominate the market with a share of 48.2%, followed by Europe. The large share of this geographical segment is attributed to factors such as growing consumption of illicit drugs, the availability of government funding to curb drug abuse, laws supporting drug screening, the growing burden of accidents due to alcohol impairment, and the presence of key players in the region are driving the growth of the drug screening market in this region.

Recent Developments

  • Quest Diagnostics and Select Health of South Carolina entered into an agreement to expand Select Health’s laboratory network for its Medicaid and Medicare-Medicaid dual-eligible enrollees and to enhance access to diagnostics information services for members.
  • LabCorp Entered into a multi-year agreement with Infirmary Health (US) to offer laboratory testing services in the eastern Gulf Coast.
  • Psychemedics introduced a vaping panel test that detects the ingestion of marijuana, CBD, and nicotine drugs by all methods, including electronic cigarettes or smoking
  • Thermo Fisher Scientific introduced CEDIA Mitragynine (Kratom) Assay for the detection of Kratom for criminal justice and forensic use only
  • Omega Laboratories introduced the Omega Hair 17-panel drug test capable of detecting 45 different substances, including eight commonly abused variants of benzodiazepines

Speak to Analyst: